Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 95
Selected: 0
NCT IDTitle
NCT02451007Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
NCT03838744Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
NCT04383119Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
NCT00060944A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
NCT05101265Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
NCT05841563Clinical Trial of PM54 in Advanced Solid Tumors Patients.
NCT05121740Extension Study in a Cohort of Adult Patients With COVID-19 Infection
NCT01405391Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
NCT01222767Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
NCT01970540Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
NCT02210364Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
NCT04358237Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
NCT05063318Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
NCT02929394Trabectedin Maintenance Post 1st-line in STS
NCT01102426Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
NCT01299636Study of PM060184 in Patients With Advanced Solid Tumors
NCT01980667Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
NCT00050427A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
NCT05835609PM534 Administered Intravenously to Patients With Advanced Solid Tumors
NCT02204111Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
NCT01149681Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
NCT03127215Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors
NCT05153239Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
NCT02421588Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
NCT00050414A Study of Trabectedin in Patients With Advanced Ovarian Cancer
NCT05705167Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)
NCT00580112An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
NCT01951157A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
NCT03590210Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas
NCT00796120An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
NCT00027508Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
NCT02194231ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)
NCT00113607An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
NCT02100657Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
NCT01379989INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
NCT05572476Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
NCT02448537A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
NCT00786838A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
NCT01314599Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
NCT01876043Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
NCT00884845Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
NCT02533674Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
NCT06524583Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
NCT02249702Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma
NCT06766825Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC)
NCT03085225Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
NCT05285033RW Effectiveness of Lurbinectedin in Extensive Stage SCLC
NCT03117361Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
NCT02809339Improving Quality of Care for Patients With Recurrent Ovarian Cancer
NCT00359294A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma